“kite-pharma” Archives

in
Entry Author Date Location
Juno Dissects ROCKET Deaths, Will Aim Better CAR-T at Leukemia 11/10/17 Seattle
FDA Lifts Hold on Cellectis’s “Off the Shelf” CAR-T, With Caveats 11/07/17 New York
ASH Sneak Peeks: Novartis, Juno Update CAR-T Lymphoma Competition 11/01/17 National
Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal 10/20/17 National
Kite Nabs First Adult CAR-T Approval With Notable Uptick Of Cures 10/18/17 National
Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T 09/05/17 New York
Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More 09/01/17 National
To Be More Than Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles 08/28/17 San Francisco
Gilead Makes Long-Awaited Splash With $12B Bet on Kite, Cell Therapy 08/28/17 San Francisco
Unanimous Advice To FDA: Approve Landmark CAR-T Cancer Therapy 07/12/17 National
ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity 06/06/17 National
Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More 05/12/17 National
Kite CAR-T Death: An Unwelcome Mystery as FDA Mulls Approval 05/08/17 National
Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More 04/21/17 National
Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge 04/18/17 Seattle
AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down 04/06/17 National
Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More 03/31/17 National
Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? 03/13/17 National
Bio Roundup: Healthcare Is Hard, “Slow” FDA, Drugging RNA & More 03/03/17 National
After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy 03/01/17 Seattle
With Eye On FDA, Kite Says CAR-T For Lymphoma Holds Up After 6 Months 02/28/17 National
Armed with $16M, Cue Biopharma Aims for Selective Immunotherapy 01/24/17 Boston
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
TCR2 Therapeutics Unveils New Cancer Therapy Approach and $44.5M Round 12/08/16 Boston
At Late-Night ASH Talk, Juno Execs Look Beyond Stalled “Rocket” Trial 12/06/16 Seattle
In Year of CAR-T Trouble, Can Bluebird, Penn Make Headway in Myeloma? 11/30/16 Boston
Two More Deaths In Trial Halt Juno’s Top CAR-T Treatment Again 11/23/16 Seattle
All In One Place: A New Immuno-Oncology Trial Resource 10/19/16 National
Checkpoints In Lung Cancer, and Other Oncology News From Europe 10/11/16 National
Page 1 of 3 next page »